# Boule Diagnostics > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/boulediagnostics). ## Overview Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics. The company is unique in the diagnostics market for conducting its own development, manufacturing, and marketing of instruments and consumables for blood diagnostics. Boule primarily serves hospitals, clinics, laboratories, and other diagnostics companies, offering complete systems for hematology in both human and veterinary areas. With strong positions in emerging markets like Asia, Boule has been expanding its presence in the fast-growing veterinary market. ## Products & services • Hematology analyzers for human diagnostics • Veterinary diagnostics instruments • OEM reagents and blood controls • Consumables for diagnostic instruments • Calibration and quality control products - **Human Diagnostics** (55%) — Includes hematology analyzers and consumables for human blood diagnostics. - **Veterinary Diagnostics** (20%) — Instruments and consumables for veterinary blood diagnostics. - **OEM Solutions** (15%) — Contract development and manufacturing of reagents and blood controls. - **Consumables** (10%) — Includes calibration and quality control products for diagnostics. - Hematology analyzers for human diagnostics - Veterinary diagnostics instruments - OEM reagents and blood controls - Consumables for diagnostic instruments - Calibration and quality control products ## Customers Boule Diagnostics serves a diverse range of customers, including hospitals, clinics, laboratories, and other diagnostics companies. These customers rely on Boule for complete blood diagnostics systems that offer reliability and accuracy. The company's products are particularly valued in emerging markets where access to decentralized diagnostics is crucial. Boule's veterinary diagnostics solutions also cater to the growing demand in the animal healthcare sector. The company's focus on OEM solutions attracts other diagnostics companies seeking high-quality reagents and blood controls. - **Hospitals and Clinics** (primary) — Purchase hematology analyzers and consumables for patient diagnostics. - **Veterinary Clinics** (secondary) — Use veterinary diagnostics instruments for animal health. - **OEM Customers** (emerging) — Contract for reagents and blood controls manufacturing. - Hospitals seeking reliable blood diagnostics systems - Clinics needing decentralized diagnostics solutions - Laboratories requiring accurate hematology analyzers - Veterinary clinics expanding into animal diagnostics - Diagnostics companies looking for OEM reagents and controls ## Geography Boule Diagnostics operates globally with subsidiaries in Sweden, the United States, Mexico, and Russia. The company has a strong presence in emerging markets, particularly in Asia, where demand for decentralized diagnostics is growing. Boule's products are distributed in over 100 countries through a network of distributors, supported by local sales and service teams. This extensive geographic reach allows Boule to tap into diverse markets, mitigating risks associated with regional economic fluctuations. - Global operations with subsidiaries in Sweden, USA, Mexico, and Russia - Strong presence in emerging markets, especially Asia - Products distributed in over 100 countries - Local sales and service teams support global distribution - Geographic diversity helps mitigate regional economic risks ## Strategy Boule Diagnostics is focused on expanding its installed base of instruments and enhancing its multi-brand strategy. The company is transitioning to strategic partnerships to access cutting-edge technologies, aiming to bring competitive products to market faster. Boule is also sharpening its focus on the OEM market for reagents and blood controls, which presents significant growth opportunities. The company is committed to operational improvements to stabilize profitability and deliver value to shareholders. - **Expand Installed Base** (medium-term) — To increase market penetration and recurring revenue from consumables. - **Strategic Partnerships** (long-term) — To accelerate access to new technologies and broaden product portfolio. - **Focus on OEM Market** (medium-term) — To capture growth opportunities in reagents and blood controls. - Expand installed base of diagnostic instruments - Enhance multi-brand strategy for market competitiveness - Form strategic partnerships for technology access - Focus on OEM market for reagents and blood controls - Improve operational efficiency to stabilize profitability ## Risks Boule Diagnostics faces several risks, including currency fluctuations, particularly the impact of a weaker US dollar on revenues. The company is also exposed to risks from delayed customer payments and inventory adjustments by distributors. Additionally, the diagnostics industry is subject to regulatory changes and competitive pressures, which could affect market dynamics. Boule's reliance on emerging markets introduces geopolitical and economic risks that could impact operations. - **Currency Fluctuations** [high] — Weaker USD impacts revenue and profitability. - **Delayed Payments** [medium] — Affects cash flow and delivery schedules. - **Regulatory Changes** [high] — Could alter market access and compliance costs. - Currency fluctuations impacting revenue, especially USD - Delayed customer payments affecting cash flow - Inventory adjustments by distributors causing sales volatility - Regulatory changes in the diagnostics industry - Geopolitical and economic risks in emerging markets ## Accounting Boule Diagnostics applies IFRS standards, with critical accounting areas including revenue recognition and capitalized development expenditures. The timing of revenue recognition can be affected by currency fluctuations and customer payment delays, impacting quarterly results. The company capitalizes development costs, which are subject to amortization and potential write-downs, affecting net income. Boule's financial statements are also influenced by lease accounting under IFRS 16, impacting reported liabilities and assets. - **Revenue Recognition** - **Capitalized Development Expenditure** - **Lease Accounting (IFRS 16)** - Revenue recognition affected by currency fluctuations and payment delays - Capitalized development expenditures subject to amortization and write-downs - Lease accounting under IFRS 16 impacts liabilities and assets - Quarterly results influenced by timing of revenue and cost recognition --- *Last updated: 2026-08-11T04:04:51.341016+00:00*